FLGT:NSD-Fulgent Genetics Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 17.86

Change

0.00 (0.00)%

Market Cap

USD 0.53B

Volume

0.27M

Analyst Target

USD 16.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-20 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 33.82B
NTRA Natera Inc

N/A

USD 18.10B
ICLR ICON PLC

N/A

USD 14.94B
ILMN Illumina Inc

N/A

USD 11.75B
MEDP Medpace Holdings Inc

N/A

USD 8.68B
EXAS EXACT Sciences Corporation

N/A

USD 8.47B
GH Guardant Health Inc

N/A

USD 5.39B
RDNT RadNet Inc

N/A

USD 3.68B
SHC Sotera Health Co

N/A

USD 2.98B
WGS GeneDx Holdings Corp.

N/A

USD 2.71B

ETFs Containing FLGT

EXSH:XETRA iShares STOXX Europe Sele.. 5.26 % 0.00 %

N/A

USD 0.35B
LDUK:LSE L&G Quality Equity Divide.. 5.17 % 0.00 %

N/A

USD 0.05B
IUKD:SW iShares UK Dividend UCITS.. 5.06 % 0.00 %

N/A

USD 0.89B
UKDV:SW SPDR® S&P UK Dividend Ar.. 4.88 % 0.00 %

N/A

USD 0.09B
SXIPEX:SW iShares STOXX Europe 600 .. 2.56 % 0.00 %

N/A

USD 0.09B
EXH5:XETRA iShares STOXX Europe 600 .. 2.41 % 0.00 %

N/A

USD 0.30B
WDIV SPDR® S&P Global Dividen.. 1.48 % 0.40 %

N/A

USD 0.19B
WDIV:AU SPDR S&P Global Dividend 1.41 % 0.00 %

N/A

USD 0.28B
FDD First Trust STOXX® Europ.. 0.00 % 0.57 %

N/A

N/A
IUKD:LSE iShares UK Dividend UCITS 0.00 % 0.00 %

N/A

USD 0.89B
UKDV:LSE SPDR S&P UK Dividend Aris.. 0.00 % 0.00 %

N/A

USD 0.09B
XASX:LSE Xtrackers - Xtrackers MSC.. 0.00 % 0.00 %

N/A

N/A
EXH5:F 0.00 % 0.00 %

N/A

N/A
EXSH:F iShares STOXX Europe Sele.. 0.00 % 0.00 %

N/A

N/A
IQQD:F iShares UK Dividend UCITS 0.00 % 0.00 %

N/A

N/A
ISPA:F iShares (DE) I - iShares .. 0.00 % 0.00 %

N/A

N/A
SPYG:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.00 %

N/A

N/A
IQQD:XETRA iShares UK Dividend UCITS 0.00 % 0.00 %

N/A

N/A
SPYG:XETRA SPDR S&P UK Dividend Aris.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.30% 78% C+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.30% 78% C+ 66% D+
Trailing 12 Months  
Capital Gain -12.28% 57% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.28% 57% F 44% F
Trailing 5 Years  
Capital Gain 21.33% 79% B- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.33% 79% B- 47% F
Average Annual (5 Year Horizon)  
Capital Gain 10.59% 67% D+ 66% D+
Dividend Return 10.59% 67% D+ 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 111.86% 27% F 17% F
Risk Adjusted Return 9.47% 60% D- 44% F
Market Capitalization 0.53B 57% F 65% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector